Under ONIOM Layers: Analysis of BCR-ABL Enzyme Inhibitors Through Bond-Critical Points and Natural Orbitals. [PDF]
MoleculesRocha KML, Nascimento ÉCM, Martins JBL.
europepmc +1 more source
Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia. [PDF]
Pathol Oncol Res, 2023 Hasanova A +5 more
europepmc +1 more source
Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib. [PDF]
Pharmaceuticals (Basel)Hajjo R +4 more
europepmc +1 more source
The silent players: Atypical <i>BCR‑ABL </i>isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review). [PDF]
Oncol RepZhou X +5 more
europepmc +1 more source
Lactate-mediated activation of GPR81 regulates BCR/Abl protein expression in chronic myeloid leukemia cells selected under low oxygen tension. [PDF]
J PatholMenegazzi G +5 more
europepmc +1 more source
Rare Atypical Ela3 BCR-ABL transcript in acute Lymphoblastic Leukemia: a case report. [PDF]
Afr Health SciXu L, Han T, Wei S, Wang N.
europepmc +1 more source
BCR-ABL tyrosine kinase inhibitors associated acute kidney injury: a pharmacovigilance study based on the FAERS database with a case report. [PDF]
BMC NephrolShi Y +7 more
europepmc +1 more source
Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors. [PDF]
PLoS One, 2023 Wang Y +7 more
europepmc +1 more source
Design, Docking Analysis, and Structure-Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions. [PDF]
MoleculesPhilipova I +6 more
europepmc +1 more source